Optimal chemotherapy for women with breast cancer: The plot thickens

Journal of Clinical Oncology

Volumn 21, Issue 6, 2003, Pages 963-964

  Pater, Joseph L ^a   Pritchard, Kathleen I ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CMF REGIMEN; DRUG DERIVATIVE; TAC PROTOCOL; TAXOID;

ADD ON THERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; BREAST TUMOR; CHEMISTRY; CONFIDENCE INTERVAL; FEMALE; METHODOLOGY; NOTE; STATISTICAL ANALYSIS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DATA INTERPRETATION, STATISTICAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; PACLITAXEL; RECEPTORS, ESTROGEN; RESEARCH DESIGN; TAXOIDS; TREATMENT OUTCOME;

EID: 0037445129     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.067     Document Type: Editorial

References (9)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
2. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
3. Nolvadex Adjuvant Trial Organisation: Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: Interim analysis at four years. Lancet 1:257-261, 1983
4. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
5. Henderson C, Berry D, Demetri G, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:xxx-xxx, 2003
6. Piccart MJ, Lohrisch C, Duchateau L, et al: Taxanes in the adjuvant treatment of breast cancer: Why not yet. J Natl Cancer Inst Monogr 30:88-95, 2001
7. Goldhirsch A, Coates AS, Colleoni M, et al: Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. J Clin Oncol 16:1358-1362, 1998
8. Citron M, Berry D, Cirrincione C, et al: Superiority of dose-dense over conventional scheduling and equivalence of sequential vs combination adjuvant chemotherapy for noe-positive cancer (CALGB 9741, INT C9741). Breast Cancer Res Treat 76:532, 2002 (abstr 15)
9. Lippman ME, Allegra JC, Thompson EB, et al: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978